HC Wainwright & Co. Reiterates Buy on ALX Oncology Holdings, Raises Price Target to $17.5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on ALX Oncology Holdings (NASDAQ:ALXO) and raised the price target from $16 to $17.5.
October 03, 2023 | 4:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The 'Buy' rating on ALX Oncology Holdings has been reiterated by HC Wainwright & Co., with a price target increase from $16 to $17.5.
The reiteration of the 'Buy' rating and the increase in price target by HC Wainwright & Co. indicates a positive outlook for ALX Oncology Holdings. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100